Filing Flows › Citius Pharmaceuticals (CTXR) › R&D spending
Citius Pharmaceuticals (CTXR) R&D spending by quarter
Citius Pharmaceuticals' R&D spending was $1.1M in Q3 FY26 (third quarter fiscal 2026), -35% from Q2 FY26. Over the last 3 quarters it ranged from $1.1M (Q3 FY26) to $1.6M (Q2 FY26).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 FY26 | $1.1M | -35% | — |
| Q2 FY26 | $1.6M | +2% | — |
| Q1 FY26 | $1.6M | — | — |
Q3 FY26 at a glance
Citius Pharmaceuticals, Q3 FY26: revenue $1.5M, operating margin -785.4%, net loss $11.9M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Citius Pharmaceuticals' R&D spending?
Citius Pharmaceuticals' R&D spending was $1.1M in Q3 FY26 (third quarter fiscal 2026), -35% from Q2 FY26.
How has Citius Pharmaceuticals' R&D spending changed?
Over the last 3 quarters it ranged from $1.1M (Q3 FY26) to $1.6M (Q2 FY26).
Q3 FY26 results → · How Citius Pharmaceuticals makes money →